Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $237000.0.

  • Champions Oncology's Net Income towards Common Stockholders fell 6744.51% to $237000.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $2.4 million, marking a year-over-year increase of 50652.17%. This contributed to the annual value of $4.7 million for FY2025, which is 16460.97% up from last year.
  • Latest data reveals that Champions Oncology reported Net Income towards Common Stockholders of $237000.0 as of Q4 2025, which was down 6744.51% from -$466000.0 recorded in Q3 2025.
  • In the past 5 years, Champions Oncology's Net Income towards Common Stockholders ranged from a high of $4.5 million in Q1 2025 and a low of -$2.6 million during Q3 2023
  • For the 5-year period, Champions Oncology's Net Income towards Common Stockholders averaged around -$365250.0, with its median value being -$245500.0 (2021).
  • In the last 5 years, Champions Oncology's Net Income towards Common Stockholders skyrocketed by 2760000.0% in 2021 and then tumbled by 1284375.0% in 2023.
  • Over the past 5 years, Champions Oncology's Net Income towards Common Stockholders (Quarter) stood at $277000.0 in 2021, then tumbled by 105.78% to -$16000.0 in 2022, then plummeted by 12843.75% to -$2.1 million in 2023, then skyrocketed by 135.15% to $728000.0 in 2024, then tumbled by 67.45% to $237000.0 in 2025.
  • Its Net Income towards Common Stockholders was $237000.0 in Q4 2025, compared to -$466000.0 in Q3 2025 and -$1.8 million in Q2 2025.